New drugs and dosage forms

April 2012
American Journal of Health-System Pharmacy;4/1/2012, Vol. 69 Issue 7, p538
Academic Journal
The article reports new drugs including Mifepristone tablets, cortisol-receptor blocker for controlling hyperglycemia; Pancrelipase tablets, for treating exocrine pancreatic insufficiency in adults with chronic pancreatitis or pancreatectomy and Testosterone gel, for replacement therapy in conditions related to deficiency or absence of endogenous testosterone.


Related Articles

  • Chronic pain meds lower testosterone levels.  // Clinical Advisor;Apr2013, Vol. 16 Issue 4, p16 

    The article discusses a study by Andrea L. Rubinstein and colleagues, which revealed that men taking long-acting opioids were nearly five times more likely to become hypogonadal than men taking short-acting opioids.

  • Investigational drugs may expand medical treatment of Cushing's syndrome. Owens, Colleen // Endocrine Today;Dec2011, Vol. 9 Issue 12, p1 

    The article focuses on mifepristone and pasireotide, two investigational drugs that have the potential to treat Cushing's syndrome, according to endocrinology experts.

  • Growth hormones.  // Reactions Weekly;9/30/2006, Issue 1121, p13 

    The article presents a case report of a girl patient who developed acute pancreatitis after growth hormone treatment, based on a study by C. De Beaufort, P. Beck, R. Seligmann, R. de Meirleir and J. De Schlepper in the September 2006 issue of the "Journal of Pediatrics." A description of...

  • Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies.  // Human Reproduction;Feb2009, Vol. 24 Issue 2, p425 

    Topically applied testosterone gels are a widely used mode of testosterone replacement therapy. A concern associated with the use of testosterone gel is unintentional transfer to children or women by skin contact with the application site. We present a case of female hyperandrogenism most likely...

  • Post-menopausal hormone gel well tolerated.  // Modern Medicine;Mar97, Vol. 65 Issue 3, p4 

    Looks at a new natural-progesterone vaginal gel for post-menopausal women who experience difficult side effects from synthetic hormone replacement therapy. Absorption and application mechanics; Comments from Columbia Laboratories chairman William Bologna.

  • Mifepristone (Korlym).  // AHFS Consumer Medication Information;Apr2018, p1 

    Mifepristone (Korlym) is used to treat hyperglycemia (high blood sugar) in people with a certain type of Cushing's syndrome in which the body makes too much cortisol (a hormone) and who have failed surgery or cannot have surgery to treat this condition. Mifepristone is in a class of medications...

  • Novel Extended-Release Formulation Gellin With FDA. Rios, Maribel // Pharmaceutical Technology;Feb2004, Vol. 28 Issue 2, p16 

    Presents a novel gel-matrix-based, extended release, oral dosage form of drug-delivery system founded on Penwest's proprietary "TIMERx" platform. Technology consisting of a drug core surrounded by an agglomerated, hydrophilic complex that, when compressed, forms a controlled-release matrix...

  • Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486). van der Lely, Aart-Jan; Foeken, Karin; van der Mast, Roos C.; Lamberts, Steven W.J. // Annals of Internal Medicine;1/15/91, Vol. 114 Issue 2, p143 

    Presents case reports of Cushing syndrome patients whose acute psychosis were reversed with mifepristone or RU 486. Mechanism of action of the drug; Medical history of the patients;

  • Mifepristone demonstrated safety, efficacy in Cushing's syndrome trials.  // Endocrine Today;Feb2011, Vol. 9 Issue 2, p4 

    The article discusses a phase 3 study on the safety and effectiveness of mifepristone for treatment of patients with Cushing's syndrome.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics